Chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo-controlled studies, sorafenib is currently acknowledged worldwide as the standard therapeutic agent for advanced HCC. Following the introduction of sorafenib for the treatment of HCC, Phase III trials of numerous other agents as first-line or second-line chemotherapy have been conducted to determine if any of these agents might offer superior survival benefit to sorafenib. In 2016, a clear survival benefit of regorafenib over placebo was demonstrated in HCC patients showing disease progression after sorafenib treatment. A year later, in 2017, lenvatinib has been shown to be non-inferior to sorafenib, in terms of the overall survival, in chemo-naïve patients with advanced HCC. More recently, promising outcomes have also been reported with new agents, such as nivolumab and cabozantinib. At present, various novel combination regimens including these agents are currently under development. Hepatic arterial infusion chemotherapy (HAIC) is frequently adopted for the treatment of locally advanced HCC in Japan, based on reports of high response rates and favorable long-term outcomes. Although some randomized controlled trials of HAIC plus sorafenib vs. sorafenib alone as first-line therapy have been conducted in patients with advanced HCC, no firm evidence of the superiority of one over the other has been established yet. In the future, demonstration of the survival advantage of HAIC and the recognition of HAIC as one of the standard treatments for patients with advanced HCC are expected.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common of all malignancies and second most common cause of cancer-related death in the world (1) . It ranks fifth among the causes of death from cancer in Japan (2) . The incidence of liver cancer varies geographically, with higher incidence rates observed in less developed regions of Asia, such as East Asia or Southeast Asian countries, as compared to those in more developed regions in Europe and North America (1) . While its incidence continues to increase worldwide, the number of deaths from HCC has been gradually decreasing in Japan. The main reasons for this trend towards decrease in the rate of death from liver cancer in Japan are considered to be the widespread screening for hepatitis B or C viral infection prevalent in Japan, which interrupts the transmission of hepatitis virus infection via transfusion of blood and blood products, and the establishment of treatments for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection (3) .
Although a wide range of therapeutic options is available for HCC, chemotherapy is one of the most important treatment modalities for advanced HCC. It is employed to treat patients who are judged as being unsuitable candidates for surgical resection, local ablative therapy or transarterial chemoembolization (TACE), that is, patients who have extrahepatic metastasis, show evidence of vascular invasion, or are refractory to TACE (3) (4) (5) (6) (7) (8) . However, the efficacy of chemotherapy is still unsatisfactory and the prognosis of patients with HCC remains poor (3) (4) (5) (6) (7) (8) . Chemotherapy for HCC can be classified into systemic chemotherapy and hepatic arterial infusion chemotherapy (HAIC). In Japan, systemic chemotherapy is mainly employed for advanced HCC patients with extrahepatic metastasis, while HAIC is mainly employed for patients with localized advanced HCC, e.g., those with evidence of vascular invasion (3) (4) (5) . In regard to systemic chemotherapy ( Fig. 1) , sorafenib is the standard of care in the first-line setting for patients with advanced HCC. In 2016, 9 years after the efficacy of sorafenib was established, regorafenib came to be established as the standard care for patients showing disease progression after first-line sorafenib therapy. A year later, in 2017, lenvatinib has been shown to be non-inferior, in terms of the overall survival, to sorafenib as first-line therapy for advanced HCC, and this agent has come to be regarded as another standard treatment agent for advanced HCC. On the other hand, HAIC has been shown to have a favorable tumor-shrinking effect and to offer long-term survival, even in patients with advanced HCC (3) (4) (5) , and is frequently adopted in Japan. However, no consensus has been reached as to its place as a standard treatment for advanced HCC, because no firm evidence has been established from any randomized controlled trials. Recently, some immuno-oncologic agents such as ani-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody have begun to attract much attention in attempts at developing other effective anticancer agents. In this article, we review the present status and future perspectives of chemotherapy, including firstline and second-line systemic chemotherapy, immunotherapy and HAIC, for patients with advanced HCC.
Systemic chemotherapy: first line
Sorafenib is a multikinase inhibitor of Raf kinase, which is known to be involved in cancer cell proliferation, and also of vascular endothelial growth factor receptor-2/-3 (VEGFR-2/-3) and plateletderived growth factor receptor-beta (PDGFR-β), which are known to be involved in peritumor neovascularization (9, 10) . Two pivotal Phase III placebo-controlled studies, namely, the SHARP trial (11) and the Asia-Pacific trial (12) , whose results were presented at the Annual Meeting of the American Society of Clinical Oncology in 2007 and 2008, respectively ( Fig. 1 and Table 1 ), revealed significant prolongation of the time to progression and the overall survival in advanced HCC patients treated with sorafenib. Therefore, sorafenib came to be established as the standard therapy treatment agent for first-line therapy of patients with advanced HCC, and is available worldwide. Nonetheless, the efficacy of sorafenib remains modest: the reported median survival time is less than 1 year and the tumor response rate is less than 5%. Thus, there remains a critical and unmet need for aggressive development of newer and more effective agents for advanced HCC.
After sorafenib was established as the standard first-line treatment agent for advanced HCC, Phase III trials of sorafenib vs. a number of other molecular-targeted agents either alone or in combination, such as sunitinib (13) , brivanib (14) , linifanib (15) , sorafenib plus erlotinib (16), etc., and of combinations of molecular-targeted agents plus cytotoxic agents, such as sorafenib plus doxorubicin (17) , as first-line treatment for patients with advanced HCC were conducted (13) (14) (15) (16) (17) (18) to sorafenib (Table 1) . Recently, however, in 2017, 10 years after sorafenib was first established as showing efficacy against advanced HCC, a Phase III trial of lenvatinib vs. sorafenib demonstrated non-inferiority of lenvatinib to sorafenib in patients with advanced HCC (18) .
Sunitinib
Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β and several other related tyrosine kinases, with antitumor and antiangiogenic activities. In a Phase III trial of sunitinib vs. sorafenib (13) , the overall survival in the sunitinib arm was actually significantly inferior to that in the sorafenib arm, although the progression-free survival did not differ significantly between the two treatment arms.
Brivanib
Brivanib is the first reported orally administered selective dual inhibitor of the FGFR (fibroblast growth factor receptor) and VEGFR tyrosine kinases. In a Phase III trial of brivanib vs. sorafenib (14) , the predefined non-inferiority boundary for overall survival (non-inferiority margin, 1.08 of the upper limit of the 95% confidence interval (CI) for the hazard ratio) was not met, although the overall survival, time to progression, objective response rate and disease control rate were similar between the brivanib and sorafenib arms.
Linifanib
Linifanib is a novel ATP-competitive inhibitor of all VEGF and PDGF receptor tyrosine kinases that lacks significant activity against representative cytosolic tyrosine kinases or serine/threonine kinases. In a Phase III trial of linifanib vs. sorafenib (15) , although a similar overall survival and a significantly favorable time to progression were observed in the linifanib as compared to the sorafenib arm, the predefined non-inferiority margin for overall survival (non-inferiority margin, 1.0491) was not met.
Sorafenib plus erlotinib
Erlotinib is an orally active, potent selective inhibitor of the epidermal growth factor receptor (EGFR, HER-1)-related tyrosine kinase enzyme that would be expected to show a complementary effect to sorafenib in combined treatment, as sorafenib has no effect on the EGFR kinase activity. However, a Phase III trial of sorafenib plus erlotinib vs. sorafenib plus placebo conducted with expectation of an additional effect of erlotinib (16) failed to reveal any effect of addition of the latter drug, with rather similar overall survival times and times to progression obtained in both treatment arms.
Sorafenib plus doxorubicin
Doxorubicin is one of the key drugs used for the treatment of HCC, and is often used as a comparator in randomized controlled trials of cytotoxic agents. In a randomized Phase II trial of sorafenib plus doxorubicin vs. doxorubicin alone in patients with advanced HCC and Child-Pugh class A, the sorafenib plus doxorubicin arm showed a longer time to progression (sorafenib+doxorubicin, 6.4 months vs. doxorubicin alone, 2.8 months, P = 0.02), median overall survival (13.7 months vs. 6.5 months, P = 0.06) and median progressionfree survival (6.0 months vs. 2.7 months, P = 0.006) as compared to doxorubicin monotherapy (19) . Considering the more favorable overall survival yielded by the combination, the possibility of synergism between sorafenib and doxorubicin was considered. Therefore, 
Lenvatinib
Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases, VEGFR 1-3, FGFR 1-4, PDGFRα, Rearranged during Transfection (RET), and KIT (18, 20, 21) . The drug was shown in a Phase II trial to exert promising antitumor efficacy in both advanced HCC patients who received it as first-line therapy and as second-line treatment (21) , with a response rate of 23.9%, median time to progression of 9.4 months, and median survival time of 18.3 months. Based on the results of this Phase II trial, a global Phase III trial comparing lenvatinib and sorafenib in the first-line setting was conducted as a non-inferiority study (REFLECT) ( Table 1 ) (18). The main study subjects were patients with unresectable HCC, Barcelona Clinic Liver Cancer Group stage B or C, Child-Pugh class A, and no prior systemic therapy. The primary endpoint was the overall survival. The noninferiority margin was set at 1.08, based on the results of previous Phase III trials of sorafenib (14, 15) , with potential declaration of noninferiority if the upper limit of the 95% CI was less than 1.08. A total of 954 patients (lenvatinib: 478 patients; sorafenib: 476 patients) were enrolled and the patient characteristics were well-balanced between the two arms, except that the baseline serum AFP level was higher in the lenvatinib arm. Lenvatinib was administered at the dose of 8 mg for patients weighing less than 60 kg, or 12 mg for patients weighing ≥60 kg, and sorafenib was administered at the dose of 400 mg twice daily. The median survival was 13.6 months in the lenvatinib arm and 12.3 months in the sorafenib arm, and the hazard ratio was 0.92, with an upper limit of the 95% CI of 1.06; as this value was less than 1.08, the primary endpoint for non-inferiority was met. In addition, the adjusted hazard ratio and P value by the baseline AFP level were 0.856 and 0.0342, respectively. The progression-free survival, time to progression and overall response rate were statistically significantly more favorable in the lenvatinib arm as compared to the sorafenib arm. The incidences of hypertension, proteinuria and hepatic encephalopathy were higher in the lenvatinib arm, while the incidence of hand-foot syndrome was higher in the sorafenib arm.
Thus, lenvatinib showed non-inferiority, but not superiority, in terms of the overall survival, to sorafenib in the REFLECT trial (18) . Therefore, while both agents may be considered as standard treatment agents, at present, lenvatinib can still not replace sorafenib. Some oncologists may prefer sorafenib because they are used to administering the adverse events of sorafenib, while others may prefer using lenvatinib considering its antitumor effects and/or its costeffectiveness. The cost of lenvatinib 12 mg/day is only a half of that of sorafenib 800 mg/day in Japan, because the recommended dose of lenvatinib (12 mg/day) for patients with advanced HCC is only a half of that for patients with other types of cancer, such as thyroid cancer (24 mg/day). Which of the two agents is more frequently used for first-line treatment of HCC would depend on the market situation after lenvatinib is approved.
In the REFLECT trial (18), patients with major portal vein tumor thrombosis, bile duct invasion and involvement of ≥50% of the liver were excluded, therefore, the efficacy and safety of lenvatinib in such patients have not yet been clarified. As subsequent treatments, regorafenib has been established as offering benefit after failure of sorafenib, whereas no agent has yet been established as being beneficial after failure of lenvatinib. These issues remain to be clarified in future clinical trials. In addition, to augment the efficacy of lenvatinib, trials of combined administration of this drug with some other class of agents are warranted.
Systemic chemotherapy: second-line chemotherapy
Phase III trials of placebo vs. a variety of new agents, such as brivanib (22) , everolimus (23), ramucirumab (24), S-1 (25), ADI-PEG20 (26) and tivantinib (27, 28) , have been conducted in advanced HCC patients refractory to or intolerant of sorafenib, however, none of the agents examined has been demonstrated to offer any clear survival benefit ( Table 2 ). The single exception is that recently, regorafenib was found to offer survival benefit over placebo in a global Phase III trial of the drug in patients with advanced HCC who showed disease progression in response to sorafenib treatment (29) .
Brivanib
A double-blind, randomized, placebo-controlled trial of brivanib was conducted in HCC patients who had already received treatment with sorafenib (22) . However, while it significantly prolonged the time to progression, brivanib failed to show any significant beneficial effect on the overall survival, the primary endpoint.
Everolimus
Everolimus serves as an inhibitor of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway, which is a key regulator of cellular growth, proliferation, angiogenesis and survival. In a Phase III trial of everolimus vs. placebo in HCC patients with Child-Pugh class A in whom the disease had progressed during or after sorafenib treatment or who were intolerant of sorafenib (23) , everolimus showed no beneficial effect on either the overall survival or the time to progression.
Ramucirumab
Ramucirumab is a human IgG1 monoclonal antibody that specifically binds with a high affinity to the extracellular domain of human VEGFR-2 and blocks the interaction of VEGFR-2 with its ligands, inhibiting endothelial proliferation and migration. In a previous Phase III trial, while ramucirumab failed to offer any significant survival benefit over placebo in the whole enrolled population (24) , it prolonged the progression-free and overall survivals in the subset of patients with baseline serum α-fetoprotein concentrations of 400 ng/ml or more. Therefore, another Phase III trial of ramucirumab vs. placebo is under way in patients with elevated baseline serum α-fetoprotein concentrations (≥400 ng/ml) after first-line therapy with sorafenib (REACH-2) (NCT02435433).
S-1
S-1 is an orally administered anticancer agent consisting of a mixture of tegafur and two modulators, gimeracil and oteracil, that was developed with the aim of augmenting the antitumor effect of 5-fluorouracil (5-FU) by increasing the serum concentration of the drug and mitigating its gastrointestinal toxicity. A placebo-controlled Phase III trial of S-1 was conducted in Japan in patients with advanced HCC who were refractory to sorafenib (25) . However, no significant prolongation of the overall survival as compared to that in the placebo group was observed in the sorafenib-refractory advanced HCC patients treated with S-1, although a favorable effect on the progression-free survival was noted, and a subgroup analysis revealed a tendency towards improved overall survival in Stage III/IV and Child-Pugh class A patients.
ADI-Peg20
Arginine depletion is a putative target in HCC, which lacks the citrulline-to-arginine repleting enzyme, argininosuccinate synthetase. Pegylated arginine deiminase (ADI-PEG20), an agent that can rapidly convert arginine to citrulline, was shown, both in vitro and in vivo, to exert anti-proliferative effects in argininosuccinate synthetase-deficient cancers, such as HCC. A Phase III trial of ADI-Peg 20 plus best supportive care vs. placebo plus best supportive care has been conducted in patients with advanced HCC and Child Pugh scores of 5-7 who failed to respond to or were intolerant of prior systemic therapy (26) . This trial failed to reveal any survival benefit of ADI-Peg20 over placebo, although the drug was well-tolerated.
Tivantinib
Tivantinib (ARQ 197) is a selective, orally available, small-molecule MET inhibitor that was found to preferentially inhibit cell proliferation and induce apoptosis in human tumor cell lines expressing MET. A placebo-controlled randomized Phase II study carried out in the western countries demonstrated that as compared to placebo, tivantinib administered as a single agent delayed the time to progression in patients with advanced HCC (hazard ratio, 0.64; 90% CI 0.43-0.94) (30) . In addition, in the analysis of the subgroup of patients with MET-high tumors, the time to progression and overall survival were significantly longer in the patient group treated with tivantinib than in the placebo group (hazard ratio, 0.64; 90% CI 0.43-0.94), and more favorable results were obtained in the population with c-MET-enriched tumors than in the whole population. On the basis of the results, two Phase III trials, a global trial (27) and a Japanese trial (28) , were conducted to assess the effect of tivantinib on the overall survival in the population of HCC patients with METhigh tumors. However, no statistically significant difference in the overall or progression-free survival was found between the tivantinib and placebo arms in both trials.
Regorafenib
Regorafenib is a multikinase inhibitor that targets kinases involved in angiogenesis, such as VEGFR1-3 or TIE2, oncogenesis, such as c-kit or Ret, and the tumor microenvironment, such as PDGFR or FGFR. In 36 HCC patients in whom the disease had progressed under/after sorafenib treatment, this drug showed acceptable tolerability and evidence of antitumor activity (disease control rate, 72.2%; median time to progression, 4.3 months; median survival, 13.8 months) (31) . Therefore, a global Phase III trial of regorafenib vs. placebo was conducted in advanced HCC patients showing disease progression during/after sorafenib treatment (RESORCE) (29) . The eligibility criteria were patients with radiological progression during/after treatment with sorafenib, good tolerability of sorafenib, defined as having 'received sorafenib 400 mg/day or over for at least 20 of the last 28 days of treatment,' and Child-Pugh class A. A total of 573 patients were randomly assigned 2:1 to receive regorafenib or placebo. Regorafenib was administered at the dose of 160 mg once daily, 3 weeks on and 1 week off, every 4 weeks. The primary endpoint was the overall survival. The median survival was 10.6 months in the regorafenib arm and 7.8 months in the placebo arm, with the difference between the two arms being statistically significant (hazard ratio, 0.62; P < 0.001). Furthermore, a remarkable median survival of 26 months from the initiation of sorafenib was reported in the regorafenib arm (32). Significant differences were also seen in the overall response rate, progression-free survival and time to progression between the two treatment arms. In regard to the adverse events observed during treatment with regorafenib, the hand-foot syndrome, fatigue, hypertension, liver dysfunction, hypophosphatemia, etc., were frequently observed, but all of them were manageable and consistent with the known toxicity profile of regorafenib. In summary, sorafenib is the standard-of-care as first-line treatment for patients with advanced HCC, while lenvatinib has recently come to be acknowlegded as another standard first-line treatment agent for advanced HCC. As second-line treatment, regorafenib has recently been established as the standard-of-care for patients with advanced HCC who show disease progression during/after sorafenib treatment and good tolerability to sorafenib. Although positive results in Phase III trials have been obtained for three multikinase inhibitors, the prognosis of HCC remains unsatisfactory, and randomized controlled trials of various newer agents and new regimens, such as immune-checkpoint inhibitors and combined multikinase inhibitor therapy, are underway worldwide.
Systemic chemotherapy: future direction
At present, various molecular-targeted agents, such as cabozantinib (33) for the second-line setting, etc., are under development worldwide for the treatment of patients with advanced HCC. Individualized cancer treatment based on genome sequencing is also being undertaken in patients with advanced HCC.
Molecular-targeted agents: cabozantinib
Cabozantinib is an orally available small-molecule tyrosine kinase inhibitor that blocks phosphorylation of MET and VEGFR2. In a Phase II randomized discontinuation trial, encouraging clinical activity of the drug was demonstrated in both the first-and second-line settings in HCC patients (disease control rate, 78%; median progressionfree survival, 4.4 months; median survival, 15.1 months) (33) . Thus, further investigation in a Phase III trial has been initiated in HCC patients showing disease progression after prior systemic treatment (NCT01908426). Recently, cabozantinib has been announced that its global Phase III trial met its primary endpoint of overall survival, with a statistically significant and clinically meaningful improvement in median overall survival compared to placebo in patients with advanced HCC at the second planned interim analysis.
Individualized cancer treatments based on genome sequencing
The approach of next-genome sequencing has often been applied to other cancers, such as HER-2 inhibitors for HER-2 positive cancers, ALK inhibitors for EML4-ALK fusion, and RET inhibitors for RET fusion, to discover the underlying molecular mechanisms and identify novel oncogenes and tumor suppressors (44) . Targeted DNA and RNA sequencing of HCC has been often reported in patients with advanced HCC (45) , and it has been reported that the TERT promoter, TP53, CTNNB1, ARID1A and AXIN1 may be possible drivers of common mutations. TERT is a central driver gene and a promising molecular target in HCC, and the high-prevalence activation of the Wnt β catenin pathway in HCC cells is also a novel potential therapeutic target. In a study of the clinical and molecular backgrounds of responders to sorafenib treatment who showed significant tumor shrinkage, FGF3/FGF4 amplification was observed in 3 of the 10 HCC samples obtained from responders with evaluable DNA samples (46); therefore, FGF3/FGF4 amplification is considered to be possibly involved in the response to sorafenib. However, the expected response could not be obtained in these patients, and precision medicines, built on a centrally performed molecular portrait and molecularly selected cohorts with matched drugs, and individualized cancer treatments using moleculartargeted agents based on the results of genome sequencing, have not yet been established for patients with HCC.
Immunotherapy
The balance between co-stimulatory and co-inhibitory signals determines the degree of cytotoxic T-cell activation and intensity of the immune response. Immune checkpoint receptors are often upregulated in tumor tissues and promote evasion by the tumor of the host immune surveillance. Tumor immunotherapy is a promising, novel treatment strategy that could lead to improvements in both treatment-associated toxicities and outcomes. Among several immunotherapy agents, some immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) antibody (34) and anti-programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibody (35) , have recently been reported to provide promising outcomes.
Immuno-oncologic agents: anti-CTLA-4 antibody
CTLA-4, which is one of the immune checkpoint receptors, is expressed exclusively on activated T cells, Tregs, and naïve T cells. Tremelimumab is a monoclonal antibody that blocks CTLA-4, an inhibitory co-receptor that interferes with T cell activation and proliferation. A Phase II trial has already been conducted in HCC patients with underlying chronic HCV infection (34) . The response rate and the disease control rate were 17.6% and 76.4%, respectively, and the median time to progression was 6.48 months. Thus, a favorable treatment efficacy and good safety profile were obtained.
Immuno-oncologic agents: anti-PD-1/PD-L1 antibody
Nivolumab is a fully human IgG4 PD-1 immune-checkpointinhibitor antibody; it disrupts the interaction between PD-1 and PD-L1/PD-L2 and may restore T-cell antitumor immunity directed against tumor cells. A Phase I/II trial of nivolumab across noninfected, HCV-infected and HBV-infected advanced HCC patients has been performed (CheckMate-040) (35) . The results revealed a manageable toxicity profile of the drug in HCC patients, including those with no viral infection and those with underlying HCV or HBV infection, and favorable responses were observed across all dose levels and all etiologic cohorts. In addition, amazing a remarkable prolongation of the median survival (sorafenib-naive patients, 28.6 months; sorafenib-experienced patients, 15.6 months) was reported from an update analysis of CheckMate-040 (36) . Based on these promising results, the Food and Drug Administration (FDA) in United State has approved the use of nivolumab for advanced HCC patients who fail to respond to first-line treatment.
The efficacy/safety of monotherapy with the anti-PD-L1 antibody durvalumab has been reported, mainly in patients treated previously with sorafenib (37) . A total of 40 patients were enrolled, and the response rate and the median survival were 10% and 13.2 months, respectively.
Immunotherapy: future direction
To explore the potential usefulness of monotherapy with immunooncologic agents, a randomized Phase III trial of nivolumab vs. sorafenib as first-line treatment for patients with advanced HCC is ongoing (NCT02576509). In addition, a Phase III trial of pembrolizumab, another anti-PD-1 antibody, as compared to placebo is under way to elucidate the survival benefit offered by the drug as compared to placebo in the second-line setting (KEYNOTE-240, NCT02702401).
Various combination regimens, including anti-PD-1/PD-L1 antibody plus anti-CTLA-4 antibody and anti-PD-1/PD-L1 antibody plus molecular-targeted agents, have also been examined in some clinical trials. The combination of durvalumab plus tremelimumab has been examined in a Phase I/II trial, with the report of a favorable response rate (confirmed plus unconfirmed response rate, 25%) (38) . A Phase III trial of tremelimumab, durvalumab plus tremelimumab vs. sorafenib alone in Child-Pugh class A advanced HCC patients who are not eligible for locoregional therapy and have no history of receiving any prior systemic therapy for unresectable HCC is ongoing (HIMALAYA, NCT03298451). Combined treatment with nivolumab plus ipilimumab, an anti-CTLA-4 antibody has been reported to augment the tumor shrinkage effect and increase the progression-free survival yielded by ipilimumab monotherapy in patients with advanced melanoma (39) . Therefore, it was considered that combined ipilimumab plus nivolumab therapy may also be efficacious in advanced HCC patients, and the single-arm trial (Checkmate 040, NCT01658878) is currently underway.
Combined molecular-targeted agent plus anti-PD-1 antibody treatments are also attractive. Lenvatinib plus pembrolizumab has been reported to show promising tumor shrinkage effect in advanced endometrial carcinoma (response rate, 52.2%) (40) and renal cell carcinoma (response rate, 63%) patients (41) . Development of this regimen for treatment of advanced HCC is also expected (NCT03006926). A Phase I trial of another anti-PD-1 antibody, PDR-001, in combination with sorafenib (NCT02988440) is ongoing. Trials of other immuno-oncologic agents for targets of T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene 3 protein (LAG3), OX-40, 4-1BB, etc., are also ongoing. Thus, a number of clinical trials of immunecheckpoint inhibitors are in progress around the world.
Furthermore, it is also important to identify predictors of the responses to these immuno-oncologic agents. PD-L1 expression has been reported to be predictive of a beneficial outcome of treatment with nivolumab in patients with advanced non-small cell lung cancer (42) , and mismatch repair-deficient tumors have been shown to be highly responsive to checkpoint blockade with anti-PD-1 in patients with other solid tumors (43) . Thus, some immuno-oncologic agents have been identified as being potentially useful for systemic treatment of advanced HCC.
HAIC
As HAIC would be expected to be associated with increased local tumor concentrations and reduced systemic distribution of the administered anticancer drugs, it was considered that a stronger antitumor effect and lower incidence of systemic adverse reactions could be obtained with this treatment modality as compared to systemic chemotherapy. In Japan, HAIC is mainly employed for patients with localized advanced HCC, e.g., those with evidence of vascular invasion (3) (4) (5) , and a number of investigators have reported high response rates, favorable long-term outcomes, and acceptable toxicity profiles (Table 3) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) . However, no consensus has been reached as to its place as a standard treatment for advanced HCC, because no firm evidence in terms of the survival advantage of HAIC has been established from randomized controlled trials.
In regard to the chemotherapeutic agents/regimens used for HAIC, the optimal regimen for the treatment of advanced HCC still remains under debate (3) (4) (5) . Among the numerous chemotherapeutic regimens employed, cisplatin (CDDP) (47-51), 5-FU plus CDDP (52-58), and 5-FU plus interferon (59) (60) (61) (62) (63) (64) are the most frequently used in Japan, and high response rates and favorable long-term outcomes have been reported (Table 3) . Thus, HAIC is thought to be one of the effective treatment options for advanced HCC. Although sorafenib has been approved for the treatment of similar subjects with advanced HCC in Japan, HAIC is nonetheless still often adopted for patients with highly advanced HCC. To elucidate the usefulness of HAIC, several studies of sorafenib vs. HAIC, including randomized controlled trials of sorafenib plus HAIC using CDDP (HAIC[CDDP]) vs. sorafenib alone (65) and of sorafenib plus HAIC using 5-FU+cisplatin (HAIC[CDDP + 5-FU]) vs. sorafenib alone (66) in Japanese patients with advanced HCC have been reported recently.
Sorafenib plus HAIC[CDDP]
A multicenter open-label, randomized controlled Phase II trial of sorafenib plus HAIC[CDDP] vs. sorafenib alone was conducted in Japan (65) . Chemo-naïve advanced HCC patients having intrahepatic tumors affecting the prognosis, irrespective of the presence of extrahepatic tumors, with Child-Pugh scores of 5-7 and a performance status of 0-1 were eligible for this trial. A total of 108 patients were randomly assigned to the sorafenib plus HAIC[CDDP] arm or the sorafenib-alone arm. The primary endpoint was the overall survival. The results revealed a median survival of 10.6 months in the sorafenib plus HAIC[CDDP] arm and of 8.7 months in the sorafenib-alone arm. The hazard ratio stratified by the presence/ absence of portal vein tumor thrombosis and of extrahepatic metastases was 0.60 (P = 0.031), and the primary endpoint was met. Thus, sorafenib plus HAIC[CDDP] tended to yield a more favorable overall survival in almost all the subgroups examined as compared to sorafenib alone. The response rate as determined by an independent central review based on the modified RECIST criteria was 21.7% (12.1-34.2%) in the sorafenib plus HAIC[CDDP] arm and 7.3% (95% CI, 1.5-19.9%) in the sorafenib-alone arm (P = 0.09). Adverse events of all grades, including hematological toxicities, hyponatremia, nausea and hiccups, were more frequent in the sorafenib plus HAIC[CDDP] arm than in the sorafenib-alone arm, however, the treatment was well-tolerated.
Sorafenib plus HAIC[5-FU + CDDP]
Among the several agents available for HAIC, 5-FU plus CDDP has been the most frequently used in Japan, with a number of reports of favorable results (Table 3) (52) (53) (54) (55) (56) (57) (58) , although insertion of an indwelling catheter is essential for this treatment. The reported response rates range from 8% to 86%, and the reported median OS range from 6 months to 33 months. A favorable response rate (38.9%), favorable median time to progression (9. 
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